Abstract
Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions, and data on its usage in saphenous vein graft interventions are limited. This retrospective, observational study evaluated the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients who underwent saphenous vein graft intervention with distal protection devices. We found that bivalirudin use is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.
Original language | English |
---|---|
Pages (from-to) | 67-70 |
Number of pages | 4 |
Journal | American Journal of Cardiology |
Volume | 96 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2005 Jul 1 |
Externally published | Yes |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine